Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Sees Significant Growth in Short Interest

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) was the recipient of a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 1,720,000 shares, a growth of 34.4% from the January 31st total of 1,280,000 shares. Based on an average daily trading volume, of 192,900 shares, the short-interest ratio is presently 8.9 days. Approximately 10.1% of the company’s shares are short sold.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. RODMAN&RENSHAW upgraded shares of Telomir Pharmaceuticals to a “strong-buy” rating in a report on Thursday, February 20th. Rodman & Renshaw started coverage on shares of Telomir Pharmaceuticals in a report on Friday, February 21st. They issued a “buy” rating and a $15.00 price target on the stock.

Hedge Funds Weigh In On Telomir Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Gotham Asset Management LLC acquired a new position in shares of Telomir Pharmaceuticals during the fourth quarter valued at $28,000. Rhumbline Advisers boosted its holdings in shares of Telomir Pharmaceuticals by 105.9% during the fourth quarter. Rhumbline Advisers now owns 8,600 shares of the company’s stock valued at $35,000 after acquiring an additional 4,424 shares during the period. Corebridge Financial Inc. boosted its holdings in shares of Telomir Pharmaceuticals by 273.8% during the fourth quarter. Corebridge Financial Inc. now owns 9,613 shares of the company’s stock valued at $40,000 after acquiring an additional 7,041 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of Telomir Pharmaceuticals by 458.3% during the fourth quarter. Wells Fargo & Company MN now owns 10,044 shares of the company’s stock valued at $41,000 after acquiring an additional 8,245 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Telomir Pharmaceuticals by 279.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,699 shares of the company’s stock valued at $44,000 after acquiring an additional 7,879 shares during the period.

Telomir Pharmaceuticals Stock Up 2.0 %

Shares of NASDAQ:TELO opened at $4.13 on Thursday. Telomir Pharmaceuticals has a 52-week low of $3.11 and a 52-week high of $9.39. The company has a 50 day moving average of $4.42 and a two-hundred day moving average of $4.86. The company has a market capitalization of $122.92 million and a price-to-earnings ratio of -7.12.

Telomir Pharmaceuticals (NASDAQ:TELO) last announced its quarterly earnings data on Tuesday, February 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.05). On average, equities analysts anticipate that Telomir Pharmaceuticals will post -0.4 earnings per share for the current year.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.